2023 World Conference on Lung Cancer (Posters)-EP13.03. RWD of Atezolizumab Plus Chemotherapy in First Line SCLC

Pdf Summary

This presentation discusses a study on the use of atezolizumab, a type of immunotherapy, in combination with chemotherapy as a first-line treatment for small cell lung cancer (SCLC). SCLC is an aggressive form of lung cancer that has traditionally had poor survival rates. The standard treatment for SCLC consisted of platinum and etoposide, but the IMPOWER 133 trial showed that the addition of atezolizumab to chemotherapy improved overall survival (OS) and progression-free survival (PFS).<br /><br />The study included 118 patients with SCLC who were treated with atezolizumab and chemotherapy between October 2021 and November 2022. The majority of patients were male, with a median age of 64 years. Most patients had a good performance status and a history of smoking. Common comorbidities included chronic obstructive pulmonary disease (COPD) and cardiovascular factors such as diabetes and hypertension.<br /><br />The primary tumor was most often located on the right side, and all patients had metastatic disease, with the most common sites being the bone, liver, lung, adrenal gland, and brain. The most common treatment regimen used was carboplatin combined with etoposide and atezolizumab. Some patients also received radiotherapy, with holocranial radiotherapy being the most frequent type.<br /><br />After the first four cycles of treatment, the majority of patients had a partial response, and only a small percentage experienced disease progression. Around 40% of patients received a second-line treatment, with platinum retreatment and irinotecan being the most common regimens.<br /><br />With a median follow-up of 16 months, the median OS was 10 months and the PFS for the first-line treatment with atezolizumab plus chemotherapy was 5 months. The PFS for the second-line treatment was 2 months.<br /><br />The study concludes that the real-world data replicates the results of the IMPOWER 133 trial, demonstrating the benefit of adding atezolizumab to chemotherapy as a first-line treatment for SCLC. This combination therapy shows improved survival rates in a population with comorbidities and reflects real-world therapeutic management.

Asset Subtitle

Ruth Alvarez Cabellos

Meta Tag

Speaker Ruth Alvarez Cabellos

Topic SCLC & Neuroendocrine Tumors: First Line Therapy

Keywords

atezolizumab

immunotherapy

chemotherapy

small cell lung cancer

SCLC

IMPOWER 133 trial

overall survival

progression-free survival

metastatic disease

combination therapy